The SHAPE study, analyzing real-world prescribing data, found: At 3 months: tirzepatide users lost 5.9% of body weight versus 3.6% for semaglutide At 6 months: 10.1% versus 5.8% At 12 months: 15.3% versus 8.3% These are averages from actual patients, not trial participants
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes
Mounjaro is a brand-name prescription medication containing tirzepatide, made by Eli Lilly
However, rapid or significant weight loss might not be everyones goalespecially for those who fall outside of the drugs typical target market of people who are overweight or obese
The pen itself, an alcohol swab, a cotton ball or gauze, and a sharps container
[2,4] This is the period in which people can become falsely reassured